Gamida steps up search for ‘strategic alternatives’ despite stem cell therapy reaching market
Despite finally getting an off-the-shelf bone marrow stem cell transplant for blood cancer patients to market last year, cash-strapped Gamida Cell is continuing to search for a financial life raft.